Connect your agent to akta.pro and build company lists like this across sectors and geos.
The top 15 most active VC and CVC investors in US Biotech, ranked by distinct funding events observed in akta.pro News Signals over the Jan 1–Sep 25, 2026 window, with deal count, lead posture, round capital and observed focus for each. Data compiled Sep 25, 2026.
Editorial list · Coverage: US-headquartered Biotech companies · Filter: VC + CVC investors only · Ranked by: Deal count · Data source: akta.pro News Signals · Updated: Sep 25, 2026
Investors tracked 15 US Biotech · ranked by deal count Disclosed funding $1.7B+ cumulative round capital across the top 15 Top-ranked investor Catalio Capital Management 2 deals · $351M disclosed Search VC type Observed focus Sort by Top 15 active VC investors Distinct events · normalized investor names · ranked top 15 VCs| # | Investor | Deals | Round capital* | Type | Observed focus | Investments in window | Latest deal | News sources |
|---|---|---|---|---|---|---|---|---|
| 01 | Catalio Capital Management New York, NY | 2 | $351M disclosed rounds | VC | AI Drug Discovery Women's Health Diagnostics | Enveda Biosciences $311M Sep 24, 2026 | 4 articles · 4 publishers | |
| 02 | GV Mountain View, CA | 2 | $230M disclosed rounds | CVC | Bispecific Antibodies / Mast Cell Disease T-Cell Engager / Autoimmune | Santa Ana Bio $168M Sep 14, 2026 | 2 articles · 2 publishers | |
| 03 | RA Capital Management Boston, MA | 2 | $555M disclosed rounds | VC | Oncology Antibodies Ophthalmology Biologics | Solstice Oncology $225M Sep 10, 2026 | 3 articles · 3 publishers | |
| 04 | Pfizer Ventures New York, NY | 2 | $124.5M disclosed rounds | CVC | T-Cell Engager / Autoimmune Peptide-Drug Conjugates / Oncology | TwoStep Therapeutics $62.5M Sep 9, 2026 | 3 articles · 3 publishers | |
| 05 | Deep Track Capital Stamford, CT | 2 | $162M disclosed rounds | VC | Oral GLP-1 / Obesity T-Cell Engager / Autoimmune | Oblenio Bio $62M Jun 25, 2026 | 2 articles · 2 publishers | |
| 06 | SOSV Princeton, NJ | 2 | $14.5M disclosed rounds | VC | Epigenetic Oncology / Pediatric Brain Cancer Oncology Target Discovery | TippingPoint Biosciences $4.5M Mar 31, 2026 | 2 articles · 2 publishers | |
| 07 | Kickstart Salt Lake City, UT | 1 | $4.5M disclosed rounds | VC | Genomic AI | Codebreaker Labs $4.5M Sep 25, 2026 | 1 article · 1 publisher | |
| 08 | DFJ Growth Menlo Park, CA | 1 | $75M disclosed rounds | VC | AI Protein Design / Oncology | BigHat Biosciences $75M Sep 24, 2026 | 2 articles · 2 publishers | |
| 09 | Premji Invest Bangalore, India | 1 | $75M disclosed rounds | VC | AI Protein Design / Oncology | BigHat Biosciences $75M Sep 24, 2026 | 2 articles · 2 publishers | |
| 10 | 108 BioCapital New York, NY | 1 | — disclosed rounds | VC | Cell & Gene Therapy Monitoring | CellsBin — Sep 22, 2026 | 1 article · 1 publisher | |
| 11 | Draper Associates San Mateo, CA | 1 | $15.5M disclosed rounds | VC | Stem Cell Rejuvenation / Longevity | HexemBio $15.5M Sep 22, 2026 | 2 articles · 2 publishers | |
| 12 | Korea Investment Partners Seoul, South Korea | 1 | $15.5M disclosed rounds | VC | Stem Cell Rejuvenation / Longevity | HexemBio $15.5M Sep 22, 2026 | 1 article · 1 publisher | |
| 13 | Signet Healthcare Partners New York, NY | 1 | — disclosed rounds | VC | Biologics Manufacturing Technology | Primrose Bio — Sep 22, 2026 | 1 article · 1 publisher | |
| 14 | Sante Ventures Austin, TX | 1 | $37M disclosed rounds | VC | Neurorestorative Therapy / Brain Injury | ReEmerge $37M Sep 15, 2026 | 1 article · 1 publisher | |
| 15 | U.S. Venture Partners Menlo Park, CA | 1 | $37M disclosed rounds | VC | Neurorestorative Therapy / Brain Injury | ReEmerge $37M Sep 15, 2026 | 2 articles · 2 publishers |
Biotechnology & Biologics covers companies developing therapeutics, diagnostics, and platform technologies derived from living systems -- monoclonal antibodies, cell and gene therapies, RNA/mRNA medicines, protein engineering, and AI-enabled drug discovery -- as distinct from small-molecule pharmaceutical manufacturers (Pharmaceuticals) and lab-services/CRO-CDMO providers (Life Science Tools & Services). This run scopes to US-headquartered, privately held biotech companies raising private equity funding rounds; publicly listed biotechs' follow-on offerings, PIPEs, IPOs, non-dilutive grants, and licensing deals were excluded from investor qualification.
Companies are tagged against standard industry codes and against akta.pro’s internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICS and SIC codes are standard, cross-industry federal classification systems used for cross-referencing against public filings and procurement records. akta.pro’s internal taxonomy is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.